Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ribosomal protein L19 pseudogene 20 (RPL19P20) is a processed pseudogene derived from the ribosomal protein L19 (RPL19) gene. Like other ribosomal protein pseudogenes, RPL19P20 does not code for a functional protein, contains sequence homology to RPL19, and is the result of genomic DNA duplication or retrotransposition. These pseudogenes are distributed throughout the genome and typically lack biological activity or regulatory function. Unlike the parent RPL19 gene, which is involved in ribosome function and has been implicated in cancer and other diseases, RPL19P20 has no known coding capacity, cellular role, or disease relevance. RPL19P20 is not a therapeutic target, does not produce a functional protein, and has no known physiological or pathological significance. Its main relevance is as a genomic feature reflecting the history of ribosomal protein gene retrotransposition.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein L19 pseudogene 20 (RPL19P20).